bioMérieux – Business review for the nine months ended September 30, 2015

Sales

Consolidated sales rose to €1,412 million in the first nine months of 2015 from €1,193 million in the year-earlier period, an increase of 18.3% as reported and of 8.3% at constant exchange rates and scope of consolidation. After nine months of operations, bioMérieux growth excluding BioFire reached 4.5% year-on-year. BioFire contributes by around 400 basis points to the Group’s growth.

• Robust growth in nine-month sales:
  • Sales reached €1,412 million
  • Up 18.3% as reported
  • Up 8.3% at constant exchange rates and scope of consolidation
• Solid momentum in the Americas and EMEA1 regions in the third quarter
• Significant operational advances:
  • FDA clearance of the 4th FilmArray® panel: Meningitis/Encephalitis
  • Commercial launch of VIDAS® 3 in the United States
  • Deployment of capital expenditures as planned
• Organic sales growth objective should end the year around 6.5%

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux continued to drive very satisfactory organic sales growth over the first nine months of the year, with a more than 8% gain for the period. This sales performance reflects our effectively balanced product portfolio and geographic positions, as well as FilmArray®’s remarkable performance. Given this robust growth dynamic and based on our nine-month sales, organic sales growth objective should end the year around 6.5%."

Download the Full Press Release: